The new plant will give Novartis end-to-end capabilities centered on North Carolina, where it plans to have five facilities ...
Amgen has launched a late-stage program to test the feasibility of switching patients from weekly GLP-1 injections to its own ...
Katherine Szarama, who has served as Prasad’s deputy at the Center for Biologics Evaluation and Research since December, joins a long list of temporary leaders at the Department of Health and Human ...
On the heels of several big buys, Merck still has eyes for M&A—particularly in the oncology, immunology and cardiometabolic ...
The FDA has renewed calls for Amgen’s Tavneos to be pulled from the market, saying it has discovered new evidence that study ...
GENEVA-- (BUSINESS WIRE)--Alcon Inc. (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see ...
Amylin drugs have become the next big thing in obesity. Eli Lilly CEO David Ricks, understandably, thinks his rivals don’t ...
After delaying a late-stage readout last year due to “irregularities” at certain study sites, pivotal data for Bristol Myers ...
The patient death occurred outside the U.S. and was deemed unrelated to Newron Pharmaceuticals’ investigational schizophrenia ...
Members of the FDA’s Oncologic Drugs Advisory Committee questioned AstraZeneca’s trial design of switching treatments earlier ...
UniQure plans to submit AMT-130 to the U.K.’s Medicines and Healthcare products Regulatory Agency in the third quarter of ...
Chiesi Group is taking KalVista Pharmaceuticals under its wing, paying $1.9 billion for the biotech’s oral therapy Ekterly to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results